Complement c5a receptor facilitates cancer metastasis by altering t-cell responses in the metastatic niche

Cancer Research

Volumn 74, Issue 13, 2014, Pages 3454-3465

  Vadrevu, Surya Kumari ^a   Chintala, Navin K ^a   Sharma, Sharad K ^a   Sharma, Priya ^a   Cleveland, Clayton ^a   Riediger, Linley ^a   Manne, Sasikanth ^a   Fairlie, David P ^e   Gorczyca, Wojciech ^c,d   Almanza, Othon ^b   Karbowniczek, Magdalena ^a   Markiewski, Maciej M ^a  

^a TEXAS TECH UNIVERSITY   (United States)

^b Clinical Pathology Associates   (United States)

^c Bioreference Laboratory   (United States)

^d Regional Cancer Care Associates   (United States)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOMODULATION; INTERSTITIAL PNEUMONIA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; TH2 CELL;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMPLEMENT C5A; FEMALE; IMMUNOSUPPRESSION; INTERLEUKIN-10; LIVER NEOPLASMS; LUNG; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASM METASTASIS; RECEPTOR, ANAPHYLATOXIN C5A; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84904015491     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0157     Document Type: Article

References (47)

1. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
2. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
4. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 2006;66:11089-93.
5. Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, et al. Gr- 1φCD11bφ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 2010;70: 6139-49.
6. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res 2012;72: 1384-94.
7. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
8. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300.
9. Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, et al. Primary tumor hypoxia recruits CD11bφ/Ly6Cmed/Ly6Gφ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 2012;72:3906-11.
10. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008;10: 1349-55.
11. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, et al. S1PR1- STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 2012;21:642-54.
12. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
13. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev 2013;32:449-64.
14. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007;171:715-27.
15. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008;9:1225-35.
16. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001;Chapter 20:Unit 20 2.
17. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007;152:429-48.
18. Lim J, Iyer A, Suen JY, Seow V, Reid RC, Brown L, et al. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J 2013;27:822-31.
19. Reid RC, Abbenante G, Taylor SM, Fairlie DP. A convergent solution- phase synthesis of the macrocycle Ac-Phe-[Orn-Pro-D-Cha- Trp-Arg], a potent new antiinflammatory drug. J Org Chem 2003; 68:4464-71.
20. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
21. Seung E, Cho JL, Sparwasser T, Medoff BD, Luster AD. Inhibiting CXCR3-dependent CD8φ T cell trafficking enhances tolerance induction in a mouse model of lung rejection. J Immunol 2011;186:6830-8.
22. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008;8:142-52.
23. Thatte J, Dabak V, Williams MB, Braciale TJ, Ley K. LFA-1 is required for retention of effector CD8 T cells in mouse lungs. Blood 2003; 101:4916-22.
24. Paixao-Cavalcante D, Hanson S, Botto M, Cook HT, Pickering MC. FactorHfacilitates the clearance ofGBMbound iC3b by controlling C3 activation in fluid phase. Mol Immunol 2009;46:1942-50.
25. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012;22:275-81.
26. Massague J. TGFb signalling in context. Nat Rev Mol Cell Biol 2012; 13:616-30.
27. Padua D, Massague J. Roles of TGFb in metastasis. Cell Res 2009; 19:89-102.
28. Shevach EM. Mechanisms of foxp3φ T regulatory cell-mediated suppression. Immunity 2009;30:636-45.
29. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al.Conversion of peripheral CD4φCD25- naive T cells to CD4φCD25φ regulatory T cells by TGF-b induction of transcription factor Foxp3 J Exp Med 2003;198:1875-86.
30. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients. A new perspective on an old dilemma. Trends Immunol 2009;30:286-92.
31. Kim DY, Martin CB, Lee SN, Martin BK. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle. Cancer Immunol Immunother 2005; 54:1026-37.
32. Ostrand-Rosenberg S. Cancer and complement. Nat Biotechnol 2008;26:1348-9.
33. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012;22: 33-40.
34. Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012;14:994-1004.
35. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
36. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-97.
37. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4φ T cells. Immunity 2008;28:425-35.
38. Strainic MG, Shevach EM, An F, Lin F, Medof ME. Absence of signaling into CD4(φ) cells via C3aR and C5aR enables autoinductive TGF-b1 signaling and induction of Foxp3(φ) regulatory T cells. Nat Immunol 2013;14:162-71.
39. Kwan WH, van der Touw W, Paz-Artal E, Li MO, Heeger PS. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med 2013;210: 257-68.
40. Weaver DJ Jr., Reis ES, Pandey MK, Kohl G, Harris N, Gerard C, et al. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol 2010;40:710-21.
41. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7-13.
42. Banerjee A, Vasanthakumar A, Grigoriadis G. Modulating T regulatory cells in cancer: how close are we. Immunol Cell Biol 2013;91:340-9.
43. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr- 1φCD115φ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumorbearing host. Cancer Res 2006;66:1123-31.
44. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79.
45. Dunkelberger J, Zhou L, Miwa T, Song WC. C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity. J Immunol 2012;188: 4032-42.
46. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013;190:3783-97.
47. Kohl J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr Opin Mol Ther 2006;8:529-38.